Objectives: To analyse the epidemiology of isolates of serotype 6C among invasive pneumococci isolated from children and adults in Spain between 1997 and 2009, and to characterize serotype 6C clones and macrolide and quinolone resistance mechanisms.
Introduction
Streptococcus pneumoniae is a major human pathogen causing pneumonia, bacteraemia and meningitis worldwide. 1 The capsular polysaccharide of the pneumococcus is known to be an important virulence factor, and associations of capsular serotypes with the severity of invasive pneumococcal disease (IPD) have been described. 2, 3 The incidence of IPD is more frequent among children ,2 years of age and in the elderly. 4 In 2007 a new pneumococcal serotype, 6C, was described, its capsule gene locus being very similar to the 6A locus except for the wciN gene. 5, 6 This new serotype is well established among invasive and non-invasive isolates in the USA and has been retrospectively identified in isolates from 1980. 6 Although several studies in Europe have analysed the carriage rates of this new serotype in children, 7 -10 data on invasive disease remain scarce. 11 -13 In Spain, the paediatric 7-valent pneumococcal conjugate vaccine (PCV7) was licensed in June 2001, but it was not included in the public routine paediatric vaccination schedule, except for children who were at a high risk of IPD. By 2006, reported vaccine uptake had increased to 50% due to private practice.
14 Moreover, in November 2006 a universal paediatric vaccination campaign was introduced in the Autonomous Region of Madrid. 15 Since the introduction of PCV7, the incidence of IPD caused by PCV7 serotypes has decreased in Spain, although an increase in IPD caused by non-vaccine serotypes has been documented in both children and adults. 16, 17 As a consequence, resistance to b-lactams, co-trimoxazole and chloramphenicol has fallen among invasive pneumococci. 17, 18 However, while macrolide resistance has decreased in paediatric isolates it has remained stable in isolates from adults. 19 Given that macrolide resistance genes are usually carried by transposons of the Tn916 family, this resistance may spread to previously susceptible clones. 20 Another factor involved in the spread of macrolide resistance is the emergence of non-vaccine serotypes (such as 19A or 6C) carrying macrolide-resistance determinants. 18, 21 The Spanish Pneumococcal Reference Laboratory receives invasive pneumococci from all over the country on a voluntary basis. Trends for serotypes and antimicrobial resistance of invasive pneumococci collected between 1979 and 2007 were recently published, but serotype 6C was not analysed. 18 This study investigates the presence of serotype 6C among invasive pneumococci collected at the Spanish Reference Laboratory between 1997 and 2009. The aims of this study were: (i) to analyse trends for serotypes 6A, 6B and 6C among invasive pneumococci isolated before and after the introduction of PCV7 in Spain; (ii) to characterize serotype 6C clones that cause invasive disease; and (iii) to analyse the mechanisms of resistance to macrolides and quinolones.
Materials and methods

Bacterial isolates and serotyping
All invasive pneumococci received at the Spanish Pneumococcal Reference Laboratory between 1997 and 2009 were serotyped by the Quellung reaction. The available 6A isolates were screened for serotype 6C by PCR, as described previously. 22 
Susceptibility testing
Susceptibility to penicillin, cefotaxime, erythromycin, clindamycin, tetracycline, chloramphenicol, ciprofloxacin and trimethoprim/sulfamethoxazole was determined by the microdilution method, following CLSI guidelines. 23 S. pneumoniae ATCC 6303 and S. pneumoniae ATCC 49619 were used as control strains.
Macrolide resistance characterization
Phenotypic characterization of macrolide-resistant isolates was performed using the double disc diffusion method, 23 in order to differentiate between resistance to 14-and 15-membered macrolides (M phenotype) and cross-resistance to macrolides, lincosamides and streptogramin B [MLSB phenotype, which can be expressed either constitutively (cMLSB) or inductively (iMLSB)]. 24 Genes encoding macrolide resistance [erm(B), erm(A) subclass erm(TR), mef(A) and mef(E)] were sought by PCR, as described previously. 25 -27 To differentiate between the mef(A) and mef(E) gene subclasses, mef gene amplicons were digested with BamHI. The tetracycline resistance gene tet(M), the promoter of the 
Quinolone resistance characterization
The characterization of quinolone resistance was performed by a restriction fragment length polymorphism method, which detects point mutations at the main quinolone resistance-determining region (QRDR) positions involved in quinolone resistance. 30, 31 Briefly, S79 and D83 mutations in the parC gene (using HinfI and SfaNI enzymes, respectively), a D435 mutation in the parE gene (using HinfI enzyme) and S81 and E85 mutations in the gyrA gene (using HinfI and MboII enzymes, respectively) were detected. 30, 31 When a point mutation was found it was confirmed by DNA sequencing. The oligonucleotide pairs parE398/parE483, parC50/ parC152, gyrA44/gyrA170 and gyrB376/gyrB512 were used to amplify and sequence parE, parC, gyrA and gyrB QRDRs, respectively. 32 
Molecular typing
Molecular typing was performed by PFGE after digestion with SmaI, as described previously. 33 PFGE patterns were visually compared with the international pneumococcal clones described by the Pneumococcal Molecular Epidemiology Network (PMEN). 34 
Multilocus sequence typing (MLST)
MLST was performed for 84 representatives of each different PFGE pattern and inferred on the basis of PFGE patterns for the other isolates, as described previously. 35 All but one macrolide-resistant isolate and all quinolone-resistant isolates were studied by MLST. Allele numbers and sequence types (STs) were assigned using the pneumococcal MLST web site. 36 
Statistical analysis
The x 2 or Fisher's exact test was used for statistical analysis, as appropriate. P,0.05 was considered statistically significant. 
Results
A total of 22964 invasive pneumococci were received at the Spanish Pneumococcal Reference Laboratory between 1997 and 2009. Over this period, 711 pneumococci were initially classified as serotype 6B and 866 as serotype 6A. Among the provisional 6A isolates, 789 (91.1%) were available for serotype PCR analysis, of which 213 were classified as serotype 6C. The proportion of provisional serotype 6A isolates subsequently identified as serotype 6C increased from 9.8% (16/163) in the pre-PCV7 period to 11.5% (37/322; P ¼0.022) in the early-PCV7 period and 42% (160/381; P,0.01) in the late-PCV7 period.
The proportions of all invasive isolates belonging to serotypes 6B, 6A and 6C were 3.1% (711/22 964), 2.8% (653/22 964) and 0.9% (213/22 964), respectively. Serotype 6C was more frequent among adults (1.0%) than children (0.6%). Figure 1 (a and b) shows the temporal trends of serotypes 6A, 6B and 6C among invasive pneumococci isolated in Spain (1997 Spain ( -2009 ) from children and adults. From 1997 a progressive decrease in the prevalence of serotype 6B was observed in both children and adults. The proportion of isolates of serotype 6A increased in the pre-PCV7 period, remained stable in the early-PCV7 period and finally decreased in the late-PCV7 period, this being the Spanish invasive serotype 6C pneumococci case for all age groups. Although the percentage of serotype 6C remained ,1% among both paediatric and adult isolates, an increase was observed in adults after 2004 and in children after January 2009. In 2009 the overall rate of serotype 6C was 2.8% (65/2349) in adult isolates and 1.8% (11/613) in paediatric isolates.
The majority (82.6%, 176/213) of serotype 6C pneumococci were isolated from adults. The sources of isolation of invasive serotype 6C isolates were blood (n ¼168, 78.9%), CSF (n¼ 23, 10.8%), pleural fluid (n¼ 9, 4.2%) and other (n¼ 13, 6.1%). Table 1 shows the in vitro activity of eight antimicrobials against serotype 6C pneumococci. The highest antimicrobial non-susceptibility for most of the antimicrobials tested was observed in the last period (2006 -09). Comparing the pre-PCV7 period with the late-PCV7 period, non-susceptibility to erythromycin (6.3% to 19.4%), clindamycin (6.3% to 15.6%) and tetracycline (6.3% to 15.0%) showed a non-statistically significant increase (Table 1) . Using oral penicillin V criteria, 77% (164/213) of the isolates were non-susceptible to penicillin (MIC range 0.12-0.5 mg/L). 23 However, penicillin-resistant isolates were not found using current penicillin parenteral criteria. 23 All serotype 6C pneumococci were susceptible to cefotaxime. A total of 40 different PFGE patterns associated with 22 different STs were found among the 213 invasive serotype 6C isolates studied (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) . After MLST analysis a major lineage related to types ST224, ST1150 and ST4821 (two single-locus variants of ST224) was identified. This major lineage accounted for 66.7% (142/213) of the isolates and included pneumococci of three major PFGE restriction profiles. This ST224/ST1150/ ST4821 clone was found throughout the study period (Table 3) . This lineage accounted for 70.0% (21/30) of the 6C isolates among children and 65.3% (115/176) of the 6C pneumococci isolated from adults. In the pre-PCV7 period this lineage was only found among adults (78.6%, 11/14 adults). In the second and third periods this lineage was found in both children (100% and 63.6%, respectively) and adults (76.9% and 61.8%, respectively). Pneumococci belonging to this lineage were associated with penicillin MICs of 0.12 mg/L. The second major lineage (ST386/ST4310/ST4825) was only found in the final period of this study (2006 -09), accounting for 11.4% (20/176) of adult isolates and none from children. All isolates of this lineage (ST386/ST4310/ST4825) presented reduced susceptibility to penicillin (MIC¼ 0.12 mg/L), and presented co-resistance to erythromycin and tetracycline related to the presence of the Tn6002 transposon (Table 2) .
Discussion
This study analysed the epidemiology of invasive pneumococci of serotypes 6A, 6B and 6C over a 13 year period (1997 -2009) and we observed important changes related to the introduction of the PCV7 vaccine in Spain. A limitation of the study is that the Spanish Reference Laboratory received pneumococci from across the country on a voluntary basis, and therefore the present collection may not be representative of all invasive disease in Spain with respect to age, geographical origin and clinical conditions. A second limitation is that the number of invasive isolates received by the Spanish Reference Laboratory increased steadily over the study period. However, the greater number of isolates tested each year enhances the interest of the data presented in this study.
Throughout the study period, proportions of serotype 6B decreased in association with the introduction of the PCV7 Table 1 . Isolates with ciprofloxacin MICs ≥4 mg/L were considered non-susceptible. 32 Spanish invasive serotype 6C pneumococci 1715 JAC vaccine for children. However, this decrease was first observed prior to the introduction of PCV7, thereby suggesting that other factors such as changes in antimicrobial use could have contributed to the decrease in serotype 6B, as has been described previously. 18 Serotype 6A increased in the pre-PCV7 period (1997 -2001) , remained stable in the early-PCV7 period (2002 -05) and decreased in the late-PCV7 period (2006-09). These data support the notion that PCV7 immunization, which contains serotype 6B, could confer cross-protection to serotype 6A, as has been observed in the USA. 37 However, other unknown factors may also have contributed to these changes. It is noteworthy that the main decrease in the percentage of serotypes 6B and 6A was observed in the late-PCV7 period when vaccine uptake was .50%. A previous report from the Spanish Reference Laboratory showed an increase in serotype 6A, but in that study serotype 6A also included serotype 6C isolates. 18 The present study shows that this increase was mainly due to an increase in serotype 6C, detected particularly in the last 2 years (2008 -09), among invasive pneumococci collected from both children and adults. Interestingly, the increase in serotype 6C was first detected in pneumococci isolated from adults (2005), and subsequently in children (2009). In agreement with previous studies from the USA, South Africa and Spain, serotype 6C was more prevalent among adult isolates than paediatric isolates. 11, 22, 37, 38 In general, the percentages of serotypes 6B, 6A and 6C found in this study are in agreement with previous reports of children's carriage in Norway and IPD studies in the USA and Spain. 9, 13, 39 Multidrug resistance among serotype 6C isolates increased in the final years of the study period, in line with what has already been verified for children's carriage in Portugal and invasive isolates in the USA. 8, 39 Here, as in previous studies, 40 we observed no high-level resistance to penicillin. Fluoroquinolone resistance was uncommon among serotype 6C isolates and only detected in adult isolates, as described previously. 32 Although fluoroquinolone resistance remains low, the fact that this antimicrobial group is extensively used means that its resistance should be especially monitored in emerging serotypes such as 6C.
Among this collection of 213 invasive 6C pneumococci, 22 different STs were found in the 13 year period. This genetic diversity is consistent with all other epidemiological studies of 6C serotype incidence worldwide. 41 However, two major lineages accounted for 76.1% (162/213) of the 6C isolates. The first lineage, related to ST224/ST1150/ST4821, was present throughout the study period, suggesting that it is a well-established clone causing IPD in Spain. This lineage has also been identified among carriers in Portugal and been shown to cause invasive disease in the USA and Spain. 8, 11, 13, 42 On the basis of eBURST analysis of serotype 6C isolates, ST152 (a single-locus variant of ST1150) may potentially represent the 'lineage founder', the first known 6C isolate being from Germany. 36 Interestingly, the first isolate of this ST was first described within serotype 19A in 1978 in South Africa from an isolate with a penicillin MIC of 0.5 mg/L. 36 In general, serotype 6C pneumococci of ST224/ ST1150/ST4821 were antibiotic susceptible (except for reduced susceptibility to penicillin-MICs of 0.12 mg/L). However, some isolates had acquired macrolide-resistance determinants, as has been described for other well-established clones in Spain. 17 The second lineage (ST386/ST4310/ST4825) emerged in 2007 (1) erm(B), mef(E), tet(M), int, xis PEN, TET, ERY, CLI (1) ST1150 (1) Tn917 (1) erm(B), tnpA, tnpR PEN, ERY, CLI (1) ST1150 (1) iMLSB ( (1) M (7) MEGA (6) mef(E) PEN, ERY (3) ST224 (1), ST473 (1), ST1616 (1) PEN, ERY, SXT (1) ST473 (1) ERY (1) ST1143 (1) ERY, SXT (1) ST1135 (1) Tn2009 (1) mef(E), tet(M), int, xis TET, ERY (1) ND (1) a PEN, non-susceptibility to penicillin; TET, non-susceptibility to tetracycline; CHL, chloramphenicol resistance; ERY, erythromycin resistance; CLI, clindamycin resistance; SXT, non-susceptibility to trimethoprim/sulfamethoxazole. b ND, not determined. 36 Isolates of the emerging clone of serotype 6C (ST386/ ST4310/ST4825) carried the Tn6002 transposon, which harbours the erm(B) and tet(M) genes, as carried by serotype 6B pneumococci of the Poland 6B -ST315 clone. 17 Moreover, a single-locus variant of ST386 (ST3396) was identified as an emerging multidrug-resistant clone of serotype 6C pneumococci colonizing healthy children in the 2006 -07 period in Portugal. 8 A minor lineage related to ST473 and carrying the mef(E) gene emerged in 2009. This lineage was also identified among serotype 6C pneumococci isolated from carriage and invasive disease in the USA and Spain. 22, 38, 42 Interestingly, ST473 and ST1143 found in this study seem to be currently circulating in Spain among invasive isolates of both serotypes 6A and 6C, 13 as reported in the USA. 22 This may indicate a common genetic exchange of the wciN-6C gene within serogroup 6. It should be emphasized that these overlaps may be underestimated worldwide because many serogroup 6 isolates in the MLST database have not been tested for serotype 6C or 6D. 36 The fact that several STs found in this collection have already been found among carriage isolates worldwide could indicate a strong selective pressure for antibiotic resistance among serotype 6C isolates. Since the diversification of the genome of pneumococcal clones takes place mainly through the accumulation of small recombinational imports from other pneumococci (usually high in the nasopharyngeal flora of children), it was expected that serotype 6C clones would be diverse. In addition, an increase in serotype 6C pneumococci among serotypes of serogroup 6 could be envisaged.
In conclusion, the decrease in the proportions of serotype 6A among children and adults suggests cross-protection and herd immunity after PCV7 immunization. Although the proportions of serotype 6C increased in the late-PCV7 period in Spain, overall percentages of this serotype remained low in all age groups. Serotype 6C antimicrobial non-susceptibility rose in the late-PCV7 period (2006 -09), due particularly to a new lineage (ST386/ST4310/ ST4825), which carried a Tn6002 transposon. The increase in serotype 6C pneumococci was associated with the spread of a pre-PCV7 ST224/ST1150/ST4821 clone. Cross-protection between serotype 6A [included in the new 13-valent pneumococcal conjugate vaccine (PCV13)] and serotype 6C has been proposed. 37, 43 Since a decrease in percentages of serotype 6A was observed after introduction of PCV7, a decrease in serotype 6C could plausibly be hypothesized over the next few years in Spain after commercialization of PCV13 in 2010. Additional data from other countries are necessary in order to increase our knowledge of the epidemiology of serotype 6C pneumococci, to estimate its invasive disease potential and to determine whether potential concerns regarding vaccine cross-protection are warranted.
